Global Intraosseous Infusion Devices Market is estimated to be valued at US$ 1,000.7 Mn in 2023, and is expected to exhibit a CAGR of 5.4% during the forecast period (2023-2030).
Analysts’ Views on Global Intraosseous Infusion Devices Market:
Intraosseous infusion is advised for cardiopulmonary resuscitation when peripheral venous access fails, which is projected to boost the global intraosseous infusion device market over the forecast period. Thh intraosseous infusion device market is rapidly increasing, owing to an increase in emergency care cases and the prevalence of chronic conditions such as severe accidents, cardiovascular ailments, obesity, and serious burns, which fuel the hospitalization chances.
Figure 1. Global Intraosseous Infusion Devices Market Share (%), By Product Type, 2023
To learn more about this report, Request sample copy
Global Intraosseous Infusion Devices Market– Drivers
Figure 2. Global Intraosseous Infusion Devices Market Share(%), By Region, 2023
To learn more about this report, Request sample copy
Global Intraosseous Infusion Devices Market- Regional Analysis
Among region, North America is estimated to hold a dominant position in the global intraosseous infusion devices market over the forecast period. North America is estimated to hold 33.5 % of the market share in 2023. The global intraosseous infusion devices market is expected to witness significant growth in the near future due to high prevalence of cardiovasular disorders, favorable health reimbursement, and increased awareness. Increasing prevalence of cancer is contributing to growth of the intraosseous infusion devices market in North America region. For instance, in 2022, according to the National Center of Health Statistics, 1,918,030 new cancer cases and 609,360 cancer deathsare projected to occur in the U.S., which includes around 350 deaths per day from lung cancer, the leading cause of cancer deaths in 2023. This is expected to increase the number of chemotherapies in the U.S., thereby, boosting demand for intraosseous infusion devices in the U.S.
Intraosseous Infusion Device Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 1,000.7 Mn |
Historical Data for: | 2018 to 2022 | Forecast Period: | 2023 to 2030 |
Forecast Period 2023 to 2030 CAGR: | 5.4% | 2030 Value Projection: | US$ 1,446.5 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
PerSys Medical, Aero Healthcare AU Pty Ltd, Teleflex Incorporated, PAVmed Inc., BIOPSYBELL S.R.L., Becton Dickinson Company, Cook Group, SAM Medical, Argon Medical Devices, Inc., Cardinal Health, Inc., StarFish Product Engineering Inc., and Medax SRL unipersonle. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Global Intraosseous Infusion Devices Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding transportation of things from one place to another.
The coronavirus or COVID-19 outbreak that started from Wuhan, China, has spread across continents, affecting various industries globally. Supply of key materials has been severely disrupted due to the forced quarantine, and lack of labor and raw materials. As the link between regional warehouses is not smooth, the transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components have affected the supply chain of the global intraosseous infusion devices market.
Moreover, the COVID-19 pandemic has impacted the global economy and in turn, the global intraosseous infusion devices market positively. Quarantines, traveling constraints, and social distancing measures are likely to lead to a steep decline in business and consumer spending.
Global Intraosseous Infusion Devices Market- Segmentation:
Global intraosseous infusion devices market report is segmented into by product type, by technology, by end user, and by region.
Among all the segmentation, the product type segment is expected to dominate the market over the forecast period due to increasing usage FAST 1 Intraosseous Infusion Devices by physicians.
Global Intraosseous Infusion Devices Market- Cross Sectional Analysis:
Key players are manufacturing intraosseous infusion devices with advanced technology in emerging economies owing to growing incidences of cardiovascular diseases and road accidents, which is driving the overall intraosseous infusion devices market across North America. For instance, in 2022, according to the data published by MedScape, in U.S., the incidence of femoral shaft fractures ranges from 9.5 to 18.9 per 100,000 annually. Moreover, approximately 250,000 proximal femur fractures occur in the U.S. annually.
Global Intraosseous Infusion Devices Market: Key Developments
In June 2023, Teleflex Incorporated, a global provider of medical technologies, received U.S. FDA 510(k) clearance for its Arrow EZ-1O needle for MR conditional labelling. The EZ-IO needle represents a critical component of Teleflex’s Arrow EZ-IO intraosseous vascular access system. It features a patented diamond tip for fast, precise and steady insertion. The system can be used when intravenous access is difficult or impossible to obtain in emergent, urgent or medically necessary cases.
Global Intraosseous Infusion Devices Market: Key Trends
Global Intraosseous Infusion Devices Market: Restraint
Global Intraosseous Infusion Devices Market - Key Players
Major players operating in the global intraosseous infusion devices market include PerSys Medical, Aero Healthcare AU Pty Ltd, Teleflex Incorporated, PAVmed Inc., Becton Dickinson Company, BIOPSYBELL S.R.L., Cook Group, SAM Medical, Argon Medical Devices, Inc., Cardinal Health, Inc., StarFish Product Engineering Inc., and Medax SRL unipersonle.
Definition: Intraosseous (IO) infusion involves injecting medication and fluids directly into the marrow of the bone by which rapid access to the vascular system can be gained. Intraosseous infusion offers several benefits when intravenous (IV) access is not possible and rapid vascular access is necessary.
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Select a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients